ECSP15050110A - Derivados de triazina - Google Patents

Derivados de triazina

Info

Publication number
ECSP15050110A
ECSP15050110A ECIEPI201550110A ECPI201550110A ECSP15050110A EC SP15050110 A ECSP15050110 A EC SP15050110A EC IEPI201550110 A ECIEPI201550110 A EC IEPI201550110A EC PI201550110 A ECPI201550110 A EC PI201550110A EC SP15050110 A ECSP15050110 A EC SP15050110A
Authority
EC
Ecuador
Prior art keywords
triazine derivatives
compounds
following formula
relates
present
Prior art date
Application number
ECIEPI201550110A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Allen Chappie
Patrick Robert Verhoest
Jamison Bryce Tuttle
Christopher John Helal
Bethany Lyn Kormos
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP15050110A publication Critical patent/ECSP15050110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ECIEPI201550110A 2013-05-02 2015-11-30 Derivados de triazina ECSP15050110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02

Publications (1)

Publication Number Publication Date
ECSP15050110A true ECSP15050110A (es) 2017-08-31

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201550110A ECSP15050110A (es) 2013-05-02 2015-11-30 Derivados de triazina

Country Status (33)

Country Link
US (3) US8933224B2 (enExample)
EP (1) EP2991989B1 (enExample)
JP (1) JP6263606B2 (enExample)
KR (1) KR101770905B1 (enExample)
CN (1) CN105164134B (enExample)
AP (1) AP2015008843A0 (enExample)
AR (1) AR096161A1 (enExample)
AU (1) AU2014261070A1 (enExample)
BR (1) BR112015027760A8 (enExample)
CA (1) CA2910759C (enExample)
CL (1) CL2015003037A1 (enExample)
CR (1) CR20150591A (enExample)
CU (1) CU20150144A7 (enExample)
DK (1) DK2991989T3 (enExample)
DO (1) DOP2015000271A (enExample)
EA (1) EA027936B1 (enExample)
EC (1) ECSP15050110A (enExample)
ES (1) ES2637816T3 (enExample)
GE (1) GEP201706675B (enExample)
MA (1) MA38559B1 (enExample)
MD (1) MD20150103A2 (enExample)
MX (1) MX2015015163A (enExample)
NI (1) NI201500157A (enExample)
NZ (1) NZ712949A (enExample)
PE (1) PE20151940A1 (enExample)
PH (1) PH12015502462A1 (enExample)
SG (1) SG11201508201VA (enExample)
TN (1) TN2015000490A1 (enExample)
TW (1) TWI508966B (enExample)
UA (1) UA111696C2 (enExample)
UY (1) UY35547A (enExample)
WO (1) WO2014177977A1 (enExample)
ZA (1) ZA201508968B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
KR20220087474A (ko) * 2019-10-21 2022-06-24 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
CN121159397A (zh) * 2025-09-18 2025-12-19 江西芜锂增致循环科技有限公司 一种应用于高钠锂比卤水中提锂的硝基化β-双酮萃取剂的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
PH12012500778A1 (en) * 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
US20130071415A1 (en) 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
JP5543039B2 (ja) 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10

Also Published As

Publication number Publication date
CA2910759C (en) 2018-01-16
UY35547A (es) 2014-11-28
TW201506027A (zh) 2015-02-16
ES2637816T3 (es) 2017-10-17
US20150353579A1 (en) 2015-12-10
CL2015003037A1 (es) 2016-04-22
CR20150591A (es) 2016-01-04
MX2015015163A (es) 2016-02-22
CN105164134A (zh) 2015-12-16
US20150080401A1 (en) 2015-03-19
TWI508966B (zh) 2015-11-21
PH12015502462A1 (en) 2016-02-22
GEP201706675B (en) 2017-05-25
CU20150144A7 (es) 2016-04-25
NI201500157A (es) 2015-11-30
EA027936B1 (ru) 2017-09-29
US9145427B2 (en) 2015-09-29
EP2991989A1 (en) 2016-03-09
KR101770905B1 (ko) 2017-08-23
PE20151940A1 (es) 2016-01-21
NZ712949A (en) 2017-04-28
CN105164134B (zh) 2017-09-22
HK1213885A1 (zh) 2016-07-15
CA2910759A1 (en) 2014-11-06
US9296761B2 (en) 2016-03-29
BR112015027760A8 (pt) 2018-05-08
WO2014177977A1 (en) 2014-11-06
AU2014261070A1 (en) 2015-10-29
US20140329820A1 (en) 2014-11-06
DOP2015000271A (es) 2016-02-29
TN2015000490A1 (fr) 2017-04-06
MD20150103A2 (ro) 2016-02-29
SG11201508201VA (en) 2015-11-27
ZA201508968B (en) 2017-11-29
MA38559B1 (fr) 2018-04-30
EP2991989B1 (en) 2017-06-28
UA111696C2 (uk) 2016-05-25
JP6263606B2 (ja) 2018-01-17
DK2991989T3 (en) 2017-07-31
US8933224B2 (en) 2015-01-13
EA201591819A1 (ru) 2016-05-31
JP2016517877A (ja) 2016-06-20
AR096161A1 (es) 2015-12-09
KR20160003234A (ko) 2016-01-08
AP2015008843A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
NI201500157A (es) Derivados de imidazo-triazina como inhibidores de pde10
DOP2018000089A (es) Amidas heterocíclicas como inhibidores de cinasas
MX2016004933A (es) Inhibidores de pirimidina del fgfr4.
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2014002770A (es) Nuevos derivados dihidroquinolina-2-ona.
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
CR20150440A (es) Nuevos derivados de piridina
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150133A (es) Amino-quinolinas como inhibidores de cinasa
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
TR201809417T4 (tr) Cb2 reseptör agonistleri olarak purin türevleri.
CR20160146A (es) Derivados de urea indol sustituido con glucopiranosil y su uso como inhibidores sglt